Prognostic Significance of the Left Ventricular Diastolic Score: A Project Baseline Health Study

Gracia Fahed, MD,[a,b,*,†] Everton Santana, MSc,[a,b,c,*] Nicholas Cauwenberghs, PhD,[c] Bettia Celestin, MD,[a,b] Megan K. Carroll, MSc,[d] Sarah A. Short, MPH,[d] Kevin M. Alexander, MD,[a,b] Shadi P. Bagherzadeh, MD,[a,b] Kenneth W. Mahaffey, MD,[a,b,e] Adrian F. Hernandez, MD,[f] Svati H. Shah, MD, MHS,[f,g] Michael Salerno, MD, PhD,[a,b] Pamela S. Douglas, MD,[f] Tatiana Kusnetsova, MD, PhD,[c] Melissa A. Daubert, MD,[f] and Francois Haddad, MD,[a,b,†] on behalf of the Project Baseline Health Study Group

*Authors contributed equally to the manuscript

†Corresponding authors

[a]Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA

[b]Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA

[c]Research Unit Hypertension and Cardiovascular Epidemiology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium

[d]Verily Life Sciences, LLC, South San Francisco, CA, USA

[e]Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA

[f]Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA

[g]Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, USA

Funding Support

The Project Baseline Health Study and this analysis were funded by Verily Life Sciences, San Francisco, California.

Author Disclosures

All authors acknowledge institutional research grants from Verily Life Sciences. MKC and SAS report employment and equity ownership in Verily Life Sciences. FH received an institutional research grant from Actelion Ltd. within the last 2 years and an institutional research grant from Precordior Ltd. KM reports grants from Verily, Afferent, the American Heart Association (AHA), Cardiva Medical Inc, Gilead, Luitpold, Medtronic, Merck, Eidos, Ferring, Apple Inc, Sanifit, and St. Jude; grants and personal fees from Amgen, AstraZeneca, Bayer, CSL Behring, Johnson & Johnson, Novartis, and Sanofi; and personal fees from Anthos, Applied Therapeutics, Elsevier, Inova, Intermountain Health, Medscape, Mount Sinai, Mundi Pharma, Myokardia, Novo Nordisk, Otsuka, Portola, SmartMedics, and Theravance outside the submitted work. AH reports grants from Verily; grants and personal fees from AstraZeneca, Amgen, Bayer, Merck, and Novartis; and personal fees from Boston Scientific outside the submitted work. NC reports grants from the Research Foundation Flanders. The other authors have no conflicts of interest to disclose.

Data Availability Statement

The deidentified PBHS data corresponding to this study are available upon request for the purpose of examining its reproducibility. Requests are subject to approval by PBHS governance.

Address for Correspondence

Francois Haddad, MD, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94304; E-mail address: fhaddad@stanford.edu; Phone: 650-723-8138

Gracia Fahed, MD, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94304; E-mail address: gfahed@stanford.edu; Phone: 650-285-8384

Running title: Left Ventricular Diastolic Dysfunction in a Community-Based Population

Word Count: 4,987

ABSTRACT

Background: Left ventricular diastolic dysfunction (LVDD) is an important predictor of cardiovascular outcomes. LVDD assessment guidelines are valuable in clinical practice, yet a significant proportion of individuals remain indeterminate.

Objectives: We aimed to develop an easy-to-use LVDD score and compare its prognostic value to American Society of Echocardiography (ASE) and European Association of Cardiovascular Imaging (EACVI) guidelines.

Methods: Participants in the Project Baseline Health Study (PBHS) were included (n=1,952). Minor and major criteria for the PBHS diastolic score (0-6 points) were defined by percentile deviation from a healthy reference cohort (n=565), including early mitral annular tissue Doppler velocity (e'), the ratio of early diastolic inflow velocity to e' (E/e'), and left atrial volume index. Multivariable Cox regression estimated associations between LVDD assessments and major adverse cardiovascular events (MACE).

Results: At enrollment, mean age was 50±16; 56% were female. LVDD according to ASE/EACVI guidelines was present in 8.4% of participants, of whom 54.3% had an indeterminate grade. PBHS diastolic scores of ≥3 and ≥4 were observed in 14.1% and 5.8%, respectively. ASE/EACVI grades 2-3 corresponded with PBHS scores >3, whereas indeterminate categories corresponded with scores of 1-5. After multivariable adjustment, both LVDD grading systems equally predicted MACE (ASE/EACVI grades 2-3: aHR 5.7 [95%CI: 3.01-10.7]; PBHS scores 4 and 5-6: aHRs 2.3 [95%CI: 1.25-4.33] and 5.3 [95%CI: 2.44-11.56], respectively).

Conclusion: The PBHS diastolic score predicted MACE similarly to the ASE/EACVI. Its simplicity and prognostic value can make it useful in clinical settings, particularly for quantifying abnormalities and risk-stratifying patients with indeterminate LVDD.

ClinicalTrials.gov Identifier: NCT03154346

Key words: diastolic dysfunction, echocardiography, community-based study, survival analysis, heart failure

ABBREVIATIONS

ASE, American Society of Echocardiography

CAC, coronary artery calcium

CVD, cardiovascular disease

E, mitral inflow velocity

E/A, early and late diastolic peak velocities of mitral inflow

E/e', mitral inflow to annular velocity ratio

EACVI, European Association of Cardiovascular Imaging

eGFR, estimated glomerular filtration rate

e', early diastolic mitral annular velocity

FLEMENGHO, Flemish Study on Environment, Genes and Health Outcomes

HFA, Heart Failure Association

HF, heart failure

HFpEF, heart failure with preserved ejection fraction

HDL-C, high-density lipoprotein-C

LAV, left atrial volume

LAVI, left atrial volume index

LVDD, left ventricular diastolic dysfunction

LVEF, left ventricular ejection fraction

MACE, major adverse cardiovascular events

NORRE, Normal Reference Ranges for Echocardiography

PBHS, Project Baseline Health Study

TDI, tissue doppler imaging

TRV, tricuspid regurgitation velocity

WASE, World Alliance Societies of Echocardiography

INTRODUCTION

Left ventricular diastolic dysfunction (LVDD) plays a central role in the assessment of patients with heart failure (HF), and dysfunction may manifest years to decades before HF symptoms appear.[1] Community-based studies have previously shown that the presence of LVDD is a predictor of future cardiovascular outcomes.[2,3] For example, in the Olmsted county study, Redfield et al. demonstrated that LVDD, often not accompanied by recognized HF, is associated with a marked increase in all-cause mortality.[2] Additionally, in a Flemish community-based cohort, Kuznetsova et al. found that epidemiologically defined LVDD was an independent predictor of cardiovascular events after adjustment for risk factors.[3]

The mechanisms underlying LVDD may include impaired ventricular relaxation, increased chamber stiffness, and/or elevated ventricular filling pressures.[4] These changes can be measured using echocardiographic parameters, including mitral inflow and tissue Doppler imaging (TDI) velocities, left atrial volume index (LAVI), and the presence of an elevated tricuspid regurgitation velocity (TRV).[5,6] The American Society of Echocardiography (ASE) and European Association of Cardiovascular Imaging (EACVI) have developed diagnostic criteria for LVDD centered around four parameters: early mitral TDI velocity (e'), the ratio of early diastolic inflow velocity to e' (E/e'), LAVI, and peak TRV.[6] In patients with normal left ventricular ejection fraction (LVEF), LVDD is classified based on a simple majority, where LVDD is present if greater than 50% of criteria are met, absent if less than 50% of criteria are met, and indeterminate if exactly 50% of criteria are met. A second algorithm grades LVDD based on the ratio of mitral inflow velocities (E/A) and the presence of a majority of E/e', LAVI, and TRV abnormalities, which is applicable to patients with reduced LVEF and those with LVDD and normal LVEF.[6]

While ASE/EACVI criteria have proven to be valuable in clinical practice, the current classification system may have some limitations. Namely, the algorithms frequently result in indeterminate classification of LVDD or, when present, indeterminate grading of LVDD, proportions of which have ranged from 20%-60% in different cohorts,[7–9] leaving the diagnosis unclear. Moreover, TRV signal is frequently not available (ie, because of the lack of significant TR), limiting diagnostic yield.[10] When absent, the simple majority system will implicitly assume its presence as abnormal, which could misclassify individuals. To address these constraints, one may consider a scoring system based on minor and major criteria focusing on higher yield signals (eg, e', E/e', and LAVI) **(Central Illustration)**. As a precedent, the Heart Failure Association (HFA) of the European Society of Cardiology has previously employed minor and major criteria for echocardiography parameters within the HFA-PEFF score to diagnose heart failure with preserved ejection fraction (HFpEF).[11]

Thus, we sought to develop a streamlined LVDD score that could have greater simplicity for clinical use, relying on more readily available parameters and obviating indeterminate classifications. We leveraged data from the Project Baseline Health Study (PBHS), a longitudinal multicenter cohort study.[12] In this sub-study, we first aimed to develop a PBHS diastolic score and test the extent of diastolic abnormality detected compared with the ASE/EACVI classification. We hypothesized that this would allow us to better characterize the LVDD indeterminate categories (class and grade) and increase the diagnostic yield. Second, we sought to quantify the strength of the associations between demographic, cardiovascular risk factors, and LVDD. Finally, we aimed to assess the prognostic significance of LVDD classified by ASE/EACVI guidelines compared with the PBHS diastolic score.

METHODS

Study Population

The design of the PBHS study has been previously detailed.[12,13] Briefly, the PBHS study enrolled 2,502 participants from an online registry of diverse adults, aiming to over-represent individuals at risk of heart disease or cancer. The study was conducted across multiple sites: Stanford University, Duke University, and the California Health and Longevity Institute, with enrolling sites in Palo Alto, California; Durham and Kannapolis, North Carolina; and Los Angeles, California. The study was approved by the Stanford University and Duke University Institutional Review Boards, and participants provided written informed consent before participation.

The inclusion and exclusion criteria for the analytic population in this PBHS sub-study are described in **Figure 1**. Considering the baseline visit, we excluded individuals without echocardiography as well as those with moderate or severe mitral valve disease, atrial fibrillation or flutter at the time of echocardiography, and a paced atrial or ventricular rhythm. Additionally, individuals who did not have available e', E/e', and LAVI measurements at enrollment were excluded, as the PBHS diastolic score necessitates these parameters. The overall study cohort included 1,952 participants. Of note, the significant loss in participants (n=457) was largely due to a study center that did not initially acquire all measurements for e' velocities. Subsequently, we defined a subset of these individuals as a reference group to derive the thresholds considered for the scoring system **(Figure 1)**. The reference group consisted of individuals who had: (1) no current or prior history of cardiovascular, pulmonary, kidney, or autoimmune diseases or active cancers; (2) no major risk factors for atherosclerotic cardiovascular diseases, including hypertension, diabetes mellitus type II, obesity (body mass index [BMI] ≥ 30 kg/m^2),

dyslipidemia (low-density lipoprotein cholesterol ≥160 mg/dL) or active smoking; and (3) a

coronary artery calcium (CAC) score <100 Agatson.

Echocardiographic Assessment

Echocardiograms were performed at each site, with the Duke Imaging Core Laboratory

providing real-time quality control. Following a standardized protocol, echocardiography

included M-mode, 2-dimensional, pulsed-wave Doppler and TDI imaging. Chamber

quantification and assessment of diastolic function was performed by Imaging Core Laboratory

personnel, blinded to patients' clinical data, using the Digisonics software platform.

Measured echocardiographic parameters included left ventricular (LV) mass using the

linear method, LV linear dimensions, biplane end-diastolic and end-systolic volumes, wall

thickness, relative wall thickness, septal and lateral e', early and late diastolic peak velocities of

mitral inflow ratio (E/A), average E/e', left atrial volumes (LAV), peak TRV, estimated right

ventricular systolic pressure, and aortic root diameters. LAV and LV volumes were measured

using the biplane Simpson method and scaled to body surface are. Intraclass correlation

coefficients reported by the Core Laboratory reproducibility assessments were 0.94 for LV end-

diastolic volume, 0.99 for LV mass, 0.96 for LV ejection fraction, and 0.94 for LAV.[13]

Diastolic Dysfunction Assessment and Minor and Major Criteria of LVDD

We evaluated LVDD using the ASE/EACVI classification, which consists of a 2-step

approach, yielding a diastolic dysfunction classification (present, absent, or indeterminate

∼*Algorithm A*[6]) and a subsequent grading of the LVDD (grade 1, 2, 3, or grade indeterminate

∼*Algorithm B*[6]). In the absence of myocardial disease or LVEF <50%, the following four criteria

were evaluated: e' velocity (septal e' <7 cm/s, lateral e' <10 cm/s), average E/e' >14, peak TRV

>2.8 cm/s, or LAVI >34 mL/m^2. LVDD was present when >50% of the criteria were met;

indeterminate, if exactly 50% of the criteria were met; and absent, if <50% of the criteria were

met. In the presence of LVDD, an LVEF <50%, or myocardial disease, dysfunction was further

graded according to the E/A ratio, E/e', peak TRV, and LAVI, following the ASE/EACVI

Algorithm B.[6]

Alternatively, we tested the performance of an empiric PBHS diastolic score. The

reference values for the major and minor criteria of the score were guided by percentile-based

cutoffs of the parameters e', E/e', and LAVI in the PBHS reference group. For major criteria

thresholds, we used values ≤2.5th percentile cut-off for septal and lateral e', and ≥97.5th

percentile cut-off for E/e' and LAVI. For minor criteria thresholds, we used values outside the

15th-85th percentile ranges. Thresholds were rounded to the closest unit while ensuring

consistency with previous recommendations, if applicable. Peak TRV was not included in the

scoring system due to the frequent unavailability of this measurement. Additionally, TRV may

lack specificity for diastolic dysfunction as elevated levels may also reflect pre-capillary

pulmonary hypertension.[14]

Outcome Assessment

Clinical events were reported by participants or confirmed by study coordinators using

pre-specified visit case report forms. Major adverse cardiovascular events (MACE) were defined

as a first cardiovascular-related event, which included composites of cardiovascular-related

mortality, atherosclerotic events, incident HF, thrombotic events, new-onset atrial fibrillation,

hypertensive emergency, pacemaker implantation, and valve replacement procedures. The

median follow-up period was 4.25 years, and the time-to-first-event was considered for analysis. We excluded participants with a reported mortality from unknown cause if they did not have any preceding cardiovascular event (competing events).

Statistical Analysis

The online Verily Terra platform (https://terra.bio/) was used to access the data, which were analyzed using the Python 3.10 environment. Baseline characteristics were presented for the overall cohort population and reference group. Continuous variables were summarized as means±standard deviation and categorical variables as frequencies and percentages. To analyze the associations between LVDD and cardiovascular risk factors, a backward stepwise logistic regression analysis was performed. Odds ratios and 95% confidence intervals (CIs) were calculated and displayed as forest plots using a $\log_2$ scale. To evaluate the association of the two LVDD grading systems with incident MACE, the Kaplan–Meier method was employed to estimate event-free probabilities and graphically depict the time-to-event data for the duration of the study follow-up. This was followed by a univariable Cox regression screen **(Supplemental Table 1)** and a multivariable Cox regression analysis to estimate the proportional adjusted hazard ratios (aHRs) and 95% CIs for the risk of MACE according to the ASE/EACVI LVDD grades and PBHS diastolic scores. The following covariables were used in all the multivariable-adjusted models: age, sex, BMI, systolic blood pressure, active smoking status, serum high-density lipoprotein (HDL) cholesterol, non-HDL cholesterol, estimated glomerular filtration rate (eGFR), lipid-lowering medication use, hypertensive medication use, history of diabetes mellitus, history of cardiovascular disease (CVD), LVEF <50%, and LV mass index. For Cox regression (lifelines 0.27.8), using grid search optimization, the values 0.1, 0.05, and 0.01 were

tested for the penalizer and L1 ratio hyperparameters, aiming at maximizing the average evaluation of the out-of-sample log-likelihood. Scaled Schoenfeld residuals were used to test proportional hazard assumptions.

To assess the clinical utility of including diastolic function evaluation in cardiovascular risk prediction, we compared a base clinical model composed of the same cardiovascular risk factors in the multivariable Cox analysis with an incremental model that incorporated the same variables plus LVDD grade/score. The comparison was conducted using likelihood-ratio chi-squared tests and adjusted Brier scores[15], with LVDD assessed using both the ASE/EACVI criteria and PBHS diastolic score.

RESULTS

Study Sample Characteristics

Table 1 presents the clinical and echocardiographic characteristics of the overall study cohort and the healthy reference group. The mean age of the participants (n=1,952) was 50±16 years; 56.3% were female; and 35.6% had hypertension, of whom 72.6% were on antihypertensive treatment. Only 31 (1.6%) individuals had an LVEF <50%. Compared with the overall study cohort, the reference sample was younger (41±14 vs. 50±16 years, p<0.001); however, both groups had similar racial and ethnic representation.

LV Diastolic Function in the PBHS Cohort

LVDD According to the ASE/EACVI Classification

In the overall cohort, LVDD was present in 164 participants (8.4%) while indeterminate classification of LVDD was observed in 115 participants (5.9%) according to the ASE/EACVI criteria. No LVDD was observed in the remaining participants. Among the participants with LVDD, grade 1 was identified in 34 individuals (20.7%), grade 2 in 36 individuals (21.9%), and grade 3 in 5 individuals (3.1%). However, an indeterminate grade was identified in the majority of participants (54.3%) (**Figure 2**). In the reference cohort, most participants (96.6%) did not have LVDD; 2.5% were classified as indeterminate for LVDD; and 0.9% met the criteria for LVDD but had an indeterminate grade (**Supplemental Figure 1**). Of note, peak TRV signal was only present in 47% of the overall cohort.

LVDD According to the PBHS Diastolic Score

To capture an ordinal classification of diastolic function, we developed a PBHS diastolic score comprising minor and major criteria for e', E/e', and LAVI. Criteria were guided by the percentiles in the reference cohort (**Supplemental Table 2**). The resultant PBHS diastolic scoring system is represented in **Figure 3A**. Minor criteria were empirically attributed 1 point in the scoring system and included septal e' velocities of 5.5-7 cm/s, lateral e' velocities of 7-10 cm/s, an average E/e' of 10-14, and a LAVI of 34-42 ml/m^2. Major criteria were empirically attributed 2 points each and included septal e' velocities <5.5 cm/s, lateral e' velocities <7 cm/s, an average E/e' >14, and a LAVI >42 ml/m^2. Although TRV was not included in the PBHS diastolic score due to its infrequent availability and poor specificity to LVDD[10,15], we tested its distribution in the PBHS population. The ASE/EACVI reference limit of 2.8 m/s corresponded to >99th percentile in our reference group (**Supplemental Table 2**).

In the overall cohort, PBHS diastolic scores of 0-1 were observed in most participants (72.3%), with 114 individuals (5.8%) having scores ≥4 **(Figure 3B)**. In the reference group, 552 participants (97.7%) had scores ≤2. When the diastolic scores were contrasted with the ASE/EACVI classification of LVDD **(Figure 3C)**, a clear concordance was noted. However, the PBHS score classified 100% of participants (ie, not indeterminate), whereas the ASE/EACVI criteria classified only 46%., the remaining were indeterminate. No participant with normal LV diastolic function according to the ASE/EACVI criteria had a PBHS diastolic score ≥4. Lower PBHS diastolic scores overlapped with no LVDD while higher scores overlapped with higher grades (ASE/EACVI grades 2-3) of LVDD. In contrast, grade 1 and indeterminate class or grade of LVDD according to the ASE/EACVI criteria had scores ranging from low to high, without a clear clustering **(Figure 3C)**.

LVDD and Major Cardiovascular Outcomes

Clinical Correlates of LVDD

Using the ASE/EACVI criteria, LVDD was associated with age, pulse pressure, non-HDL cholesterol, diabetes mellitus, hypertension, and a history of CVD **(Figure 4A)**. A history of CVD had the largest effect estimate, with a 5-fold higher odds of having LVDD according to the guidelines.

The same variables (age, pulse pressure, non-HDL cholesterol, hypertension, and a history of CVD) in addition to sex and HDL cholesterol were retained in the regression models for the PBHS diastolic score (scores ≥4 vs. <4). Age had the most pronounced effect (OR: 3.85; 95% CI: 2.51-5.89; p<0.001) **(Figure 4B)**. The observed protective effects of both non-HDL and HDL cholesterol may stem from an interaction overlooked in the model.

Cardiovascular Outcomes Analysis

After a median follow-up of 4.25 years, 98 individuals experienced at least one MACE. Among them, 54.1% were atherosclerosis-related (n=53), and 26.6% were new-onset atrial fibrillation (n=26). The remaining MACE were composites of thrombotic events (8.2%), cardiovascular intervention (valve replacement or pacemaker implantation) (7.1%), incident HF (3.1%), hypertensive emergencies (1%), and cardiovascular-related mortality (1%). **Figure 5** shows the Kaplan–Meier curves of cardiovascular event-free probabilities across the ASE/EACVI classification categories **(Figure 5A)** and across the PBHS diastolic scores **(Figure 5B)**, suggesting an incremental worse prognosis with every LVDD grade or score point increase.

Tables 2 and **3** show the univariable and multivariable aHRs for MACE based on the ASE/EACVI criteria and PBHS diastolic score. In multivariable models, individuals with an ASE/EACVI grade of indeterminate (HR: 2.49; 95%CI: 1.39-4.46; p=0.021) or grade 2 or 3 (HR: 5.67; 95%CI: 3.01-10.67; p<0.001) had a significantly higher risk of a MACE compared to individuals with no LVDD or an indeterminate LVDD class **(Table 2)**. In parallel, individuals with a PBHS diastolic score of 4 (HR: 2.32; 95%CI: 1.25-4.33; p=0.008) or scores of 5-6 (HR: 5.32; 95%CI: 2.44-11.56 p<0.001) were independently associated with a higher risk of MACE compared to individuals with scores of 2 or less **(Table 3)**. The full Cox regression analyses are displayed in **Supplemental Tables 3 and 4**, and sensitivity analyses using the backward elimination method are presented in **Supplemental Table 5**.

To evaluate the potential clinical significance of incorporating diastolic function assessment into cardiovascular risk prediction, we tested the added value that an incremental model, including LVDD, provides over a base model composed solely of the established

cardiovascular risk factors adjusted for in the Cox analysis. The likelihood-ratio chi-squared test was significant between both models when adding either the ASE/EACVI criteria or PBHS diastolic score to assess LVDD (p<0.001). Moreover, the adjusted Brier score, reflecting predictive accuracy, increased from 12% for the base model to 16.6% and 15.2% when adding LVDD defined by the ASE/EACVI criteria and PBHS diastolic score, respectively (**Figure 6A).** **Figure 6B** and **Supplemental Figure 2** display scatter plots indicating that the incremental models' effect on predicted risk was more pronounced in higher age groups compared with the base model.

DISCUSSION

Our study presents several main findings. First, in a community-based study with a multi-racial and multi-ethnic cohort, LVDD was relatively common and associated with age and cardiovascular risk factors. Second, advanced LVDD defined by the ASE/EACVI criteria and PBHS diastolic score were both predictive of MACE in our cohort. Third, the simplified PBHS diastolic score characterized LVDD differently by quantifying diastolic abnormalities on an ordinal scale, thus providing insights into the risk stratification of patients classified in the indeterminate categories of the guidelines.

Reference limits play an important role in defining thresholds for diastolic parameters, and different cohorts were studied for this purpose.[3,16–18] For LAVI, guidelines often recommend a threshold of 34 ml/m^2 to define LA enlargement, which corresponded to the 90th percentile of the NORRE cohort.[6,18] In the PBHS cohort, we found a threshold of 42 mL/m^2 for LAVI consistent with the cut-offs suggested by the World Alliance Societies of Echocardiography (WASE)[16] (41 mL/m^2) and FLEMENGHO[3] (45 mL/m^2) cohorts at their 97.5[th] percentiles. For e'

and E/e', choosing reference limits is more challenging in view of the age-related changes, and

guidelines have adopted a single threshold for simplicity. Our septal and lateral e' thresholds

were consistent with the younger age group in the WASE cohort, albeit higher values were found

in older age groups. The CAC score phenotyping in the reference group excluded more severe

subclinical cardiovascular disease than the WASE cohort, which could explain the higher e'

velocities.[16] Prior work from our group has demonstrated the association between LVDD and

subclinical CAC.[13] For the E/e' ratio, a threshold may vary depending on the intended goal:

either early detection of myocardial abnormality, high LV filling pressures, or associations with

outcomes. The 2016 ASE/EACVI guidelines evolved to adopt a threshold of 14; however,

various hemodynamic stress and epidemiologic studies support a lower threshold of 10.[2,5,19]

Diagnostic scores, such as the H2FPEF, used a cutoff of 9 to differentiate HFpEF from other

dyspnea causes.[20] Indeed, defining reference limits not only depends on the cohort, but also on

the desired balance between the specificity and sensitivity of LVDD detection. This diagnostic

balance offers clinicians options for selecting the optimal criteria to evaluate LVDD. For

example, age- and sex-adjusted criteria may be preferred for the earlier detection of LVDD,

particularly in young individuals.[3,17] In contrast, by choosing single thresholds, the ASE/EACVI

guidelines signify the adoption of age-weighted criteria, leading to a definite higher prevalence

of LVDD in the elderly, with fewer false-positives in younger individuals.[6] This study explored

an LVDD scoring approach, derived from reference parameters, that combines highly specific

and less specific thresholds as major and minor criteria, respectively.

     In our study, the presence of LVDD defined using the ASE/EACVI criteria was not

uncommon, albeit less prevalent than reported when using age- and sex-adjusted thresholds.[3,17]

As expected, we found that LVDD was associated with age and known cardiovascular risk

factors. While LVDD has been thoroughly investigated in clinical studies of symptomatic HF patients, limited studies report the prognostic importance of LVDD in the community. In a recent study of individuals with risk factors, Potter et al. showed that in addition to clinical factors, global longitudinal strain and diastolic dysfunction (defined by E/e'>15, or E/e'>10 + LAVI >34mL/m^2) are important to consider for better prediction of HF risk; doing so reclassified 61% of individuals in the intermediate-risk group into the low-risk group.[21] In the Flemish community cohort, Kuznetsova et al. found that LVDD defined by age- and sex- specific criteria correlated well with incident cardiovascular events, but not when graded using ASE/EACVI criteria.[3] In the PBHS cohort, we found that both advanced ASE/EACVI grades (indeterminate, 2-3) and high diastolic scores (≥4 points) were independently associated with MACE after full adjustment for cardiovascular risk factors. Adding diastolic function to clinical factors for cardiovascular risk assessment had a modest yet significant improvement in cardiovascular outcome predictions, with the incremental value being more pronounced in older age groups. Future research is necessary to validate these findings, and eventually inform targeted intervention strategies in patients that will benefit the most.

One caveat of the ASE/EACVI classification is the indeterminate categories and their unclear association with cardiovascular risk. Playford et al. reported that the indeterminate class and grade included up to 21.5% of individuals overall and 62.5% of individuals with reduced LVEF.[8] Chao et al. also noted a significant prevalence of indeterminate categories (43.8%) among patients referred for echocardiography at the Mayo Clinic, which they reclassified into three distinct mortality risk clusters.[7] In our cohort, indeterminate categories were common as well (54.3% of individuals with LVDD). Moreover, their corresponding PBHS diastolic scores, reflecting the extent of diastolic abnormalities in the cohort, were variable in contrast to LVDD

grade 2 and 3 for which the corresponding scores were mostly high (≥4 points) and associated with a higher risk of MACEs. Several studies trace indeterminate grading back to unmeasurable TRV.[22,23] In PBHS participants, only 46% had TRV signals where peak TRV could be quantified with high confidence. Although our study did not show the PBHS diastolic score's superiority over the ASE/EACVI guidelines when combined with clinical factors for cardiovascular risk assessment, the predictive accuracy reflected by the adjusted Brier scores was in a comparable range. Additionally, the PBHS diastolic score allowed characterization and risk stratification of indeterminate categories by quantifying their diastolic abnormalities and their subsequent association with MACE. This approach should therefore be considered in future studies, with the caveat that outcome studies should guide the weight attributed to the different parameters.

Limitations

Our analysis had several limitations. First, the PBHS diastolic score was empirically weighted with insights from epidemiology distribution, previous literature, and guidelines. Being cohort-dependent, our results benefit from further validation studies in larger population samples with varying comorbidities and a higher incidence of HF-related outcomes. Additionally, a follow-up period of more than 5 years may be needed to fully identify late-onset cardiovascular events from long-term progression of LVDD.

Despite these limitations, the PBHS cohort does exhibit several strengths, including a multicenter community cohort, a thorough core laboratory analysis, a study population enriched in metabolic risk factors, and diverse representation from multiple ethnicities and races.

CONCLUSIONS

Our study validates the prognostic value of LVDD in a community setting and demonstrates that the PBHS diastolic score could simplify the current ASE/EACVI classification if further validated. This approach can quantify diastolic abnormalities and provide insights into risk stratification, especially for patients lacking TRV measurements or patients who fall into indeterminate LVDD categories.

ACKNOWLEDGMENTS

The authors wish to thank Project Baseline Health Study participants and study sites.

REFERENCES

1. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;145(18). doi:10.1161/CIR.0000000000001063

2. Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of Systolic and Diastolic Ventricular Dysfunction in the Community: Appreciating the Scope of the Heart Failure Epidemic. *JAMA*. 2003;289(2):194. doi:10.1001/jama.289.2.194

3. Kuznetsova T, Cauwenberghs N, Sabovčik F, Kobayashi Y, Haddad F. Evaluation of diastole by echocardiography for detecting early cardiac dysfunction: an outcome study. *ESC Heart Fail*. 2022;9(3):1775-1783. doi:10.1002/ehf2.13863

4. Zile MR, Brutsaert DL. New Concepts in Diastolic Dysfunction and Diastolic Heart Failure: Part II: Causal Mechanisms and Treatment. *Circulation*. 2002;105(12):1503-1508. doi:10.1161/hc1202.105290

5. Chetrit M, Cremer PC, Klein AL. Imaging of Diastolic Dysfunction in Community-Based Epidemiological Studies and Randomized Controlled Trials of HFpEF. *JACC: Cardiovascular Imaging*. 2020;13(1):310-326. doi:10.1016/j.jcmg.2019.10.022

6. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 2016;17(12):1321-1360. doi:10.1093/ehjci/jew082

7. Chao CJ, Kato N, Scott CG, et al. Unsupervised Machine Learning for Assessment of Left Ventricular Diastolic Function and Risk Stratification. *Journal of the American Society of Echocardiography*. 2022;35(12):1214-1225.e8. doi:10.1016/j.echo.2022.06.013

8. Playford D, Strange G, Celermajer DS, et al. Diastolic dysfunction and mortality in 436□360 men and women: the National Echo Database Australia (NEDA). *Eur Heart J Cardiovasc Imaging*. 2021;22(5):505-515. doi:10.1093/ehjci/jeaa253

9. Almeida JG, Fontes-Carvalho R, Sampaio F, et al. Impact of the 2016 ASE/EACVI recommendations on the prevalence of diastolic dysfunction in the general population. *European Heart Journal - Cardiovascular Imaging*. 2018;19(4):380-386. doi:10.1093/ehjci/jex252

10. O'Leary JM, Assad TR, Xu M, et al. Lack of a Tricuspid Regurgitation Doppler Signal and Pulmonary Hypertension by Invasive Measurement. *JAHA*. 2018;7(13):e009362. doi:10.1161/JAHA.118.009362

11. Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). *Eur Heart J*. 2019;40(40):3297-3317. doi:10.1093/eurheartj/ehz641

12. Arges K, Assimes T, Bajaj V, et al. The Project Baseline Health Study: a step towards a broader mission to map human health. *npj Digit Med*. 2020;3(1):84. doi:10.1038/s41746-020-0290-y

13. Haddad F, Cauwenberghs N, Daubert MA, et al. Association of left ventricular diastolic function with coronary artery calcium score: A Project Baseline Health Study. *Journal of Cardiovascular Computed Tomography*. 2022;16(6):498-508. doi:10.1016/j.jcct.2022.06.003

14. Lam CSP, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction. *Journal of the American College of Cardiology*. 2009;53(13):1119-1126. doi:10.1016/j.jacc.2008.11.051

15. Harrell F. Statistically efficient ways to quantify added predictive value of new measurements. Published October 17, 2018. Accessed February 12, 2024.

16. Miyoshi T, Addetia K, Citro R, et al. Left Ventricular Diastolic Function in Healthy Adult Individuals: Results of the World Alliance Societies of Echocardiography Normal Values Study. *Journal of the American Society of Echocardiography*. 2020;33(10):1223-1233. doi:10.1016/j.echo.2020.06.008

17. Nayor M, Cooper LL, Enserro DM, et al. Left Ventricular Diastolic Dysfunction in the Community: Impact of Diagnostic Criteria on the Burden, Correlates, and Prognosis. *JAHA*. 2018;7(11):e008291. doi:10.1161/JAHA.117.008291

18. Kou S, Caballero L, Dulgheru R, et al. Echocardiographic reference ranges for normal cardiac chamber size: results from the NORRE study. *European Heart Journal - Cardiovascular Imaging*. 2014;15(6):680-690. doi:10.1093/ehjci/jet284

19. Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quiñones MA. Doppler Tissue Imaging: A Noninvasive Technique for Evaluation of Left Ventricular Relaxation and Estimation of Filling Pressures. *Journal of the American College of Cardiology*. 1997;30(6):1527-1533. doi:10.1016/S0735-1097(97)00344-6

20. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. *Circulation*. 2018;138(9):861-870. doi:10.1161/CIRCULATIONAHA.118.034646

21. Potter E, Huynh Q, Haji K, et al. Use of Clinical and Echocardiographic Evaluation to Assess the Risk of Heart Failure. *JACC: Heart Failure*. 2024;12(2):275-286. doi:10.1016/j.jchf.2023.06.014

22. Balaney B, Medvedofsky D, Mediratta A, et al. Invasive Validation of the Echocardiographic Assessment of Left Ventricular Filling Pressures Using the 2016 Diastolic Guidelines: Head-to-Head Comparison with the 2009 Guidelines. *Journal of the American Society of Echocardiography*. 2018;31(1):79-88. doi:10.1016/j.echo.2017.09.002

23. Luke P, Eggett C, Spyridopoulos I, Irvine T. A comparative analysis of British and American Society of Echocardiography recommendations for the assessment of left ventricular diastolic function. *Echo Res Pract*. 2018;5(4):139-147. doi:10.1530/ERP-18-0024

FIGURE LEGENDS

Figure 1. Flow chart of the Project Baseline Health Sub-Study population. The reference group excluded participants with established disease (cardiovascular, pulmonary, kidney, or autoimmune disease, or active cancers), major cardiovascular risk factors, and a coronary artery calcium score >100 Agatston.

Figure 2. Distribution of LVDD categories according to the ASE/EACVI classification in the overall Project Baseline Health Study (PBHS) cohort.

Figure 3. PBHS diastolic scoring system and overlap with ASE/EACVI classification of LVDD. (A) PBHS diastolic score. (B) PBHS diastolic score distribution. (C) Cross-table showing the overlap of the ASE/EACVI classification with the PBHS diastolic scores.

Figure 4. Association of clinical correlates with LVDD. (A) Values represent the odds of having LVDD according to the ASE/EACVI criteria. (B) Values represent the odds of having a PBHS diastolic score ≥4. Odds ratios of continuous values were scaled to half the 16th-84th percentile range, which is equal to 19 years for age, 11 mmHg for pulse pressure, 37 mg/dL for non-HDL cholesterol, and 19 mg/dL for HDL cholesterol.

Figure 5. Survival estimates: Time to major adverse cardiac events (MACE). (A) Kaplan–Meier curves of event-free probabilities for the ASE/EACVI classification and grading of left ventricular diastolic dysfunction (LVDD). Grades 2-3 were combined due to the limited number of individuals in these categories. (B) Kaplan–Meier curves of event-free probabilities for each

PBHS diastolic score. Scores 0-1 were combined due to the scarcity of incident MACE. Scores

5-6 were combined due to the limited number of individuals in these categories.

Figure 6. The value of incremental risk models considering LV diastolic function

assessments in predicting MACE. (A) Statistical performance metrics of the base model

supplemented with the PBHS diastolic score or the ASE/EACVI criteria. (B) Scatter plot of the

risk difference between the base and incremental models with the PBHS diastolic score.

*Base model cardiovascular risk factors include age, sex, body mass index, systolic blood

pressure, active smoking status, serum HDL cholesterol, non-HDL cholesterol, estimated

glomerular filtration rate, lipid-lowering medication use, hypertensive medication use, history of

diabetes mellitus, history of CVD, LVEF <50%, and LV mass index.

Central Illustration. Models of Left Ventricular Diastolic Dysfunction (LVDD) Assessments

and Cardiovascular Outcomes. (A) Concept figure: LVDD from physiology to clinical use. (B)

Distribution of the American Society of Echocardiography (ASE) and European Association of

Cardiovascular Imaging (EACVI) LVDD categories in the Project Baseline Health Study

(PBHS). (C) PBHS diastolic scoring system and overlap with ASE/EACVI LVDD categories.

(D) Kaplan–Meier of survival estimates according to the ASE/EACVI classification and PBHS

diastolic score. DT, deceleration time; e', early mitral tissue Doppler velocity; E/A, early

diastolic filling velocity to atrial contraction filling velocity ratio; E/e', the ratio of early diastolic

inflow velocity to e'; HFA, Heart Failure Association; HFpEF, heart failure with preserved

ejection fraction; GLS, global longitudinal strain; LAVI, left atrial volume index; LVMI, left

ventricular mass index; RWT, relative wall thickness.

Table 1. General characteristics of the study population

	Overall study cohort (n = 1952)	Reference group (n = 565)
General clinical data		
Age, y	50 ± 16	41 ± 14
Female, n (%)	1098 (56.3)	335 (59.3)
Body mass index, kg/m^2	28.69 ± 6.71	24.19 ± 2.9
Systolic BP, mm Hg	122.74 ± 16.32	113.47 ± 11.68
Diastolic BP, mm Hg	75.74 ± 10.26	71.38 ± 8.18
Heart rate, bpm	67.25 ± 11.54	64.84 ± 10.33
Race		
White, n (%)	1221 (62.6)	348 (61.6)
Black or African American, n (%)	337 (17.3)	53 (9.4)
Asian, n (%)	197 (10.1)	95 (16.8)
American Indian or Alaska Native	24 (1.2)	5 (0.9)
Native Hawaiian or Other Pacific Islander	20 (1.0)	7 (1.2)
Other, n (%)	153 (7.8)	57 (10.1)
Questionnaire and medical history		
Current smoker, n (%)	290 (14.9)	-
Hypertension, n (%)	694 (35.6)	-
Diabetes mellitus type 2, n (%)	294 (15.1)	-
History of CAD, n (%)	75 (3.8)	-
COPD, n (%)	63 (3.2)	-
Autoimmune disease, n (%)	93 (4.8)	-
Biochemistry		
HbA1c, %	5.7 ± 1.0	5.3 ± 0.4
Total cholesterol, mg/dL	184.4 ± 39.6	179.8 ± 29.9
LDL cholesterol, mg/dL	99.7 ± 33.9	96.2 ± 25.1
HDL cholesterol, mg/dL	58.4 ± 19.2	63.2 ± 18.1
Triglycerides, mg/dL	136.0 ± 101.3	102.2 ± 56.5
Creatinine serum, mg/dL	0.9 ± 0.3	0.8 ± 0.2
eGFR, mL/min/1.73 m^2	88.0 ± 20.3	91.6 ± 17.1
Conventional echocardiography		
LV mass index, g/m^2	70.1 ± 16.5	66.0 ± 15.1
LV ejection fraction, %	58.7 ± 4.0	58.5 ± 3.0
LV diastolic function		
E/A ratio	1.3 ± 0.5	1.5 ± 0.5
e' septal, cm/s	8.7 ± 2.6	10.5 ± 2.4
e' lateral, cm/s	11.8 ± 3.9	14.1 ± 3.7
E/e' ratio	8.0 ± 2.6	6.7 ± 1.7
LA volume index, ml/m^2	27.8 ± 7.6	27.0 ± 6.3
Coronary artery calcium		
CAC score 0, n (%)	1106 (56.7)	480 (85.0)

CAC score 0-100, n%)	441 (22.6)	85 (15.0)
CAC score 100-300, n (%)	143 (7.3)	-
CAC score ≥300, n (%)	186 (9.5)	-

Values are the mean ± standard deviation or the number of participants (%). BP, blood pressure; CAC, coronary artery calcium; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; LA, left atrial; LV, left ventricular.

Table 2. Associations of left ventricular diastolic dysfunction (LVDD) categories with MACE according to the ASE/EACVI classification

	ASE/EACVI classification of LVDD	HR (95% CI)	P-value
Unadjusted Cox analysis (c-statistic=0.67)	No LVDD	Reference	-
	LVDD Indeterminate	1.33 (0.73-2.39)	0.350
	Grade 1 LVDD	2.73 (1.11-6.73)	0.031
	Grade Indeterminate LVDD	3.40 (1.96-5.80)	<0.001
	Grade 2 or 3 LVDD	8.63 (4.81-15.47)	<0.001
Multivariable adjusted Cox analysis (c-statistic=0.84)	No LVDD/Indeterminate	Reference	-
	Grade 1 LVDD	1.00 (0.95-1.05)	0.990
	Grade Indeterminate LVDD	2.49 (1.39-4.46)	0.021
	Grade 2 or 3 LVDD	5.67 (3.01-10.67)	<0.001

Hazard ratios (HRs) represent the relative hazard for each category compared with the reference group. The multivariable model was adjusted for age, sex, body mass index, active smoking, systolic blood pressure, high-density lipoprotein (HDL) cholesterol, non-HDL cholesterol, estimated glomerular filtration rate, diabetes mellitus history, cardiovascular disease history, hypertensive medication use, lipid-lowering medication use, left ventricular hypertrophy, and left ventricular ejection fraction <50%.

Table 3. Associations of left ventricular diastolic dysfunction (LVDD) categories with MACE according to the PBHS diastolic score

	PBHS LV diastolic scoring of LVDD	HR (95% CI)	P-value
Unadjusted Cox analysis (c-statistic=0.75)	Diastolic score 0	Reference	-
	Diastolic score 1	1.00 (0.75-1.33)	0.993
	Diastolic score 2	1.19 (0.85-1.67)	0.312
	Diastolic score 3	1.61 (1.07-2.42)	0.021
	Diastolic score 4	2.58 (1.56-4.28)	<0.001
	Diastolic score 5 or 6	7.21 (3.70-14.04)	<0.001
Multivariable adjusted Cox analysis (c-statistic=0.84)	Diastolic score ≤2	Reference	-
	Diastolic score 3	1.23 (0.69-2.20)	0.483
	Diastolic score 4	2.32 (1.25-4.33)	0.008
	Diastolic score 5 or 6	5.32 (2.44-11.56)	<0.001

Hazard ratios (HRs) represent the relative hazard for each category compared with the reference group. The multivariable model was adjusted for age, sex, body mass index, active smoking, systolic blood pressure, high-density lipoprotein (HDL) cholesterol, non-HDL cholesterol, estimated glomerular filtration rate, diabetes mellitus history, cardiovascular disease history, hypertensive medication use, lipid-lowering medication use, left ventricular hypertrophy, and left ventricular ejection fraction <50%.

CENTRAL ILLUSTRATION: Models of Left Ventricular Diastolic Dysfunction (LVDD) Assessments and Cardiovascular Outcomes.

A

C

B

D

ASE/EACVI Classification of LVDD

PBHS Diastolic Score

	Minor Criteria (1 point)	Major Criteria (2 points)
Septal or Lateral e'	Septal 5.5 -7 cm/s Lateral 7-10 cm/s	Septal <5.5 cm/s Lateral <7 cm/s
Average E/e'	10-14	>14
LAVI	34-42 ml/m²	>42 ml/m²

PBHS Diastolic Score distribution

In reference

In broad

PBHS Diastolic Score	ASE classification of LVDD					
	No LVDD (n=1,673)	LVDD Indeterminate (n=115)	LVDD present (n=164)			
			Grade 1 (n=34)	Grade Indeterminate (n=89)	Grade 2 (n=36)	Grade 3 (n=5)
0	978	0	6	0	0	0
1	412	7	8	0	0	0
2	199	39	5	21	1	0
3	84	40	5	30	3	0
4	0	26	8	33	15	1
5	0	3	1	5	12	2
6	0	0	1	0	5	2

A. ASE/EACVI classification

Clinical correlates	OR (95%CI)
Age	1.89 (1.41-2.53)
Pulse pressure	1.38 (1.18-1.63)
Non-HDL cholesterol	0.81 (0.68-0.97)
Diabetes mellitus II	1.59 (1.04-2.43)
Hypertension	2.16 (1.38-3.38)
History of CVD	5.13 (3.41-7.70)

Scaled OR

B. PBHS Diastolic Score

Clinical correlates	OR (95%CI)
Age	3.85 (2.51-5.89)
Sex	0.55 (0.34-0.90)
Pulse pressure	1.36 (1.13-1.63)
Non-HDL cholesterol	0.74 (0.59-0.92)
HDL cholesterol	0.73 (0.57-0.93)
Hypertension	3.44 (1.91-6.19)
History of CVD	1.68 (1.01-2.78)

Scaled OR

A. ASE/EACVI classification

Event-free probability

Follow-up (years)

Legend: Normal, Indeterminate, Grade 1, Grade Indeterminate, Grade 2 or 3

Number at Risk

	0	1	2	3	4	5
No LVDD	1660	1569	1510	1437	1151	0
Indeterminate LVDD	112	108	108	106	92	0
Grade 1	31	30	28	27	18	0
Grade Indeterminate	85	76	69	66	58	0
Grade 2 or 3	39	32	25	22	18	0

B. PBHS Diastolic Score

Event-free probability

Follow-up (years)

Legend: Diastolic score=0-1, Diastolic score=2, Diastolic score=3, Diastolic score=4, Diastolic score=5-6

Number at Risk

	0	1	2	3	4	5
Score 0-1	1403	1325	1270	1209	965	0
Score 2	261	249	244	233	189	0
Score 3	156	146	141	137	120	0
Score 4	80	73	68	64	50	0
Score 5-6	27	22	17	15	13	0

A

Statistical metrics	Base model	Incremental model	
	CV risk factors*	Base model + PBHS Diastolic Score	Base model + ASE/EACVI criteria
Log likelihood test	128.2	146.3	155.1
Fraction of new information based on log-likelihood ratio	-	13.4%	17.3%
Adjusted Brier score	12.0 %	15.2%	16.6%
C-statistic	0.83	0.84	0.84

B

Base model: CV risk factors*
Incremental model: Base model + PBHS Diastolic Score